FIX-Triple, a gain-of-function factor IX variant, improves haemostasis in mouse models without increased risk of thrombosis

 

PDF Download Buy Article Permissions and Reprints

Summary

Engineered recombinant factor IX (FIX) with augmented clotting activity may prove useful for replacement therapy, but it has not been studied for risk of thrombosis. We used three mouse models to evaluate thrombosis risk associated with the FIX variant FIX-Triple, which has a 13-fold higher specific activity than wild-type FIX (FIX-WT). Protein infusion of FIX-Triple into haemophilia B mice was not thrombogenic, even at a dose of 13-fold higher than FIX-WT. Gene knock-in to generate mice that constitutively produce FIX-WT or FIX-Triple protein revealed that all mice expressed equal antigen levels. FIX-Triple knock-in mice that exhibited 10-fold higher FIX clotting activity did not show hypercoagulation. Adeno-associated viral (AAV) delivery of the FIX gene into mice was used to mimic gene therapy. Haemophilia B and inbred C57Bl/6 mice injected with different doses of virus particles carrying FIX-WT or FIX-Triple and expressing up to a nearly 13-fold excess (1289% of normal) of FIX clotting activity did not show increased risk of thrombosis compared with untreated wild-type mice in a normal haemostatic state. When challenged with ferric chloride (FeCl₃), the mesenteric venules of AAV-treated C57Bl/6 mice that gave a nearly five-fold excess (474%) of FIX clotting activity were not thrombotic; however, thrombosis became obvious in FeCl₃-challenged mice expressing extremely high FIX clotting activities (976–1289%) achieved by AAV delivery of FIX-Triple. These studies suggest that FIX-Triple is not thrombogenic at therapeutic levels and is a potential therapeutic substitute for FIX-WT.

• References

• 1 Hoffman R. Hematology : basic principles and practice. 4th ed. Elsevier Churchill Livingstone 2005
  PubMedGoogle Scholar
• 2 Pipe S. Consideration in hemophilia therapy selection. Semin Hematol 2006; 43: S23-27.
  PubMedGoogle Scholar
• 3 White 2nd GC. Gene therapy in hemophilia: clinical trials update. Thromb Hae-most 2001; 86: 172-177.
  Article in Thieme ConnectPubMedGoogle Scholar
• 4 Manno CS, Pierce GF, Arruda VR. et al. Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response. Nat Med 2006; 12: 342-347.
  CrossrefPubMedGoogle Scholar
• 5 Herzog RW, Mount JD, Arruda VR. et al. Muscle-directed gene transfer and transient immune suppression result in sustained partial correction of canine hemophilia B caused by a null mutation. Mol Ther 2001; 04: 192-200.
  CrossrefPubMedGoogle Scholar
• 6 Fields PA, Arruda VR, Armstrong E. et al. Risk and prevention of anti-factor IX formation in AAV-mediated gene transfer in the context of a large deletion of F9. Mol Ther 2001; 04: 201-210.
  CrossrefPubMedGoogle Scholar
• 7 Donsante A, Miller DG, Li Y. et al. AAV vector integration sites in mouse hepatocellular carcinoma. Science 2007; 317: 477
  CrossrefPubMedGoogle Scholar
• 8 Pipe SW. The promise and challenges of bioengineered recombinant clotting factors. J Thromb Haemost 2005; 03: 1692-1701.
  CrossrefPubMedGoogle Scholar
• 9 Chang JY, Monroe DM, Stafford DW. et al. Replacing the first epidermal growth factor-like domain of factor IX with that of factor VII enhances activity in vitro and in canine hemophilia B. J Clin Invest 1997; 100: 886-892.
  CrossrefPubMedGoogle Scholar
• 10 Chang J, Jin J, Lollar P. et al. Changing residue 338 in human factor IX from arginine to alanine causes an increase in catalytic activity. J Biol Chem 1998; 273: 12089-12094.
  CrossrefPubMedGoogle Scholar
• 11 Schuettrumpf J, Herzog RW, Schlachterman A. et al. Factor IX variants improve gene therapy efficacy for hemophilia B. Blood 2005; 105: 2316-2323.
  CrossrefPubMedGoogle Scholar
• 12 Lin CN, Kao CY, Miao CH. et al. Generation of a novel factor IX with augmented clotting activities in vitro and in vivo. J Thromb Haemost 2010; d doi:10.1111/j.1538-7836.2010.03913.x
  PubMedGoogle Scholar
• 13 Brunetti-Pierri N, Grove NC, Zuo Y. et al. Bioengineered factor IX molecules with increased catalytic activity improve the therapeutic index of gene therapy vectors for hemophilia B. Hum Gene Ther 2009; 20: 479-485.
  CrossrefPubMedGoogle Scholar
• 14 van Hylckama Vlieg A, van der Linden IK, Bertina RM. et al. High levels of factor IX increase the risk of venous thrombosis. Blood 2000; 95: 3678-3682.
  PubMedGoogle Scholar
• 15 Weltermann A, Eichinger S, Bialonczyk C. et al. The risk of recurrent venous thromboembolism among patients with high factor IX levels. J Thromb Haemost 2003; 01: 28-32.
  CrossrefPubMedGoogle Scholar
• 16 Ameri A, Kurachi S, Sueishi K. et al. Myocardial fibrosis in mice with over-expression of human blood coagulation factor IX. Blood 2003; 101: 1871-1873.
  CrossrefPubMedGoogle Scholar
• 17 Wang X, Cheng Q, Xu L. et al. Effects of factor IX or factor XI deficiency on ferric chloride-induced carotid artery occlusion in mice. J Thromb Haemost 2005; 03: 695-702.
  CrossrefPubMedGoogle Scholar
• 18 Gui T, Reheman A, Funkhouser WK. et al. In vivo response to vascular injury in the absence of factor IX: examination in factor IX knockout mice. Thromb Res 2007; 121: 225-234.
  CrossrefPubMedGoogle Scholar
• 19 Jin DY, Zhang TP, Gui T. et al. Creation of a mouse expressing defective human factor IX. Blood 2004; 104: 1733-1739.
  CrossrefPubMedGoogle Scholar
• 20 Chang YJ, Wu HL, Hamaguchi N. et al. Identification of functionally important residues of the epidermal growth factor-2 domain of factor IX by alanine-scanning mutagenesis. Residues Asn(89)-Gly(93) are critical for binding factor VIIIa. J Biol Chem 2002; 277: 25393-25399.
  CrossrefPubMedGoogle Scholar
• 21 Tranholm M, Kristensen K, Kristensen AT. et al. Improved hemostasis with superactive analogs of factor VIIa in a mouse model of hemophilia A. Blood 2003; 102: 3615-3620.
  CrossrefPubMedGoogle Scholar
• 22 Hoover-Plow J, Shchurin A, Hart E. et al. Genetic background determines response to hemostasis and thrombosis. BMC Blood Disord 2006; 06: 6.
  PubMedGoogle Scholar
• 23 Hemker HC, Giesen PL, Ramjee M. et al. The thrombogram: monitoring thrombin generation in plateletrich plasma. Thromb Haemost 2000; 83: 589-591.
  Article in Thieme ConnectPubMedGoogle Scholar
• 24 De Smedt E, Wagenvoord R, Coen Hemker H. The technique of measuring thrombin generation with fluorogenic substrates: 3. The effects of sample dilution. Thromb Haemost 2009; 101: 165-170.
  Article in Thieme ConnectPubMedGoogle Scholar
• 25 Xiao X, Li J, Samulski RJ. Production of hightiter recombinant adeno-associated virus vectors in the absence of helper adenovirus. J Virol 1998; 72: 2224-2232.
  PubMedGoogle Scholar
• 26 Miao CH, Thompson AR, Loeb K. et al. Long-term and therapeutic-level hepatic gene expression of human factor IX after naked plasmid transfer in vivo. Mol Ther 2001; 03: 947-957.
  CrossrefPubMedGoogle Scholar
• 27 Chauhan AK, Kisucka J, Lamb CB. et al. von Willebrand factor and factor VIII are independently required to form stable occlusive thrombi in injured veins. Blood 2007; 109: 2424-2429.
  CrossrefPubMedGoogle Scholar
• 28 Rickard KA. Guidelines for Therapy and Optimal Dosages of Coagulation-Factors for Treatment of Bleeding and Surgery in Hemophilia. Haemophilia 1995; 01: 8-13.
  PubMedGoogle Scholar
• 29 Gui T, Lin HF, Jin DY. et al. Circulating and binding characteristics of wild-type factor IX and certain Gla domain mutants in vivo. Blood 2002; 100: 153-158.
  CrossrefPubMedGoogle Scholar
• 30 Ravanat C, Freund M, Dol F. et al. Cross-reactivity of human molecular markers for detection of prethrombotic states in various animal species. Blood Coagul Fibrinolysis 1995; 06: 446-455.
  CrossrefPubMedGoogle Scholar
• 31 Mingozzi F, Liu YL, Dobrzynski E. et al. Induction of immune tolerance to coagulation factor IX antigen by in vivo hepatic gene transfer. J Clin Invest 2003; 111: 1347-1356.
  CrossrefPubMedGoogle Scholar
• 32 Franchini M, Zaffanello M, Veneri D. Recombinant factor VIIa. An update on its clinical use. Thromb Haemost 2005; 93: 1027-1035.
  Article in Thieme ConnectPubMedGoogle Scholar
• 33 O'Connell KA, Wood JJ, Wise RP. et al. Thromboembolic adverse events after use of recombinant human coagulation factor VIIa. Jama-Journal of the American Medical Association 2006; 295: 293-298.
  PubMedGoogle Scholar
• 34 Aljamali MN, Margaritis P, Schlachterman A. et al. Long-term expression of murine activated factor VII is safe, but elevated levels cause premature mortality. J Clin Invest 2008; 118: 1825-1834.
  CrossrefPubMedGoogle Scholar
• 35 Cushman M, O'Meara ES, Folsom AR. et al. Coagulation factors IX through XIII and the risk of future venous thrombosis: the Longitudinal Investigation of Thromboembolism Etiology. Blood 2009; 114: 2878-2883.
  CrossrefPubMedGoogle Scholar
• 36 Simioni P, Tormene D, Tognin G. et al. X-linked thrombophilia with a mutant factor IX (factor IX Padua). N Engl J Med 2009; 361: 1671-1675.
  CrossrefPubMedGoogle Scholar
• 37 Lusher JM. Use of Prothrombin Complex Concentrates in Management of Bleeding in Hemophiliacs with Inhibitors – Benefits and Limitations. Seminars in Hematology 1994; 31: 49-52.
  PubMedGoogle Scholar
• 38 Tsakiris DA, Scudder L, Hodivala-Dilke K. et al. Hemostasis in the mouse (Mus musculus): a review. Thromb Haemost 1999; 81: 177-188.
  Article in Thieme ConnectPubMedGoogle Scholar
• 39 Emeis JJ, Jirouskova M, Muchitsch EM. et al. A guide to murine coagulation factor structure, function, assays, and genetic alterations. J Thromb Haemost 2007; 05: 670-679.
  CrossrefPubMedGoogle Scholar
• 40 Jirouskova M, Shet AS, Johnson GJ. A guide to murine platelet structure, function, assays, and genetic alterations. J Thromb Haemost 2007; 05: 661-669.
  CrossrefPubMedGoogle Scholar
• 41 Rivard GE, Brummel-Ziedins KE, Mann KG. et al. Evaluation of the profile of thrombin generation during the process of whole blood clotting as assessed by thrombelastography. J Thromb Haemost 2005; 03: 2039-2043.
  CrossrefPubMedGoogle Scholar
• 42 Kadish JL, Wenc KM, Dvorak HF. Tissue factor activity of normal and neoplastic cells: quantitation and species specificity. J Natl Cancer Inst 1983; 70: 551-557.
  PubMedGoogle Scholar
• 43 Davidoff AM, Gray JT, Ng CY. et al. Comparison of the ability of adeno-associated viral vectors pseudotyped with serotype 2, 5, and 8 capsid proteins to mediate efficient transduction of the liver in murine and nonhuman primate models. Mol Ther 2005; 11: 875-888.
  CrossrefPubMedGoogle Scholar
• 44 Zhang TP, Jin DY, Wardrop RM 3rd. et al. Transgene expression levels and kinetics determine risk of humoral immune response modeled in factor IX knockout and missense mutant mice. Gene Ther 2007; 14: 429-440.
  CrossrefPubMedGoogle Scholar
• 45 Nathwani AC, Gray JT, Ng CY. et al. Self-complementary adeno-associated virus vectors containing a novel liver-specific human factor IX expression cassette enable highly efficient transduction of murine and nonhuman primate liver. Blood 2006; 107: 2653-2661.
  CrossrefPubMedGoogle Scholar
• 46 Wu Z, Sun J, Zhang T. et al. Optimization of self-complementary AAV vectors for liver-directed expression results in sustained correction of hemophilia B at low vector dose. Mol Ther 2008; 16: 280-289.
  CrossrefPubMedGoogle Scholar
• 47 Westrick RJ, Winn ME, Eitzman DT. Murine models of vascular thrombosis (Eitzman series). Arterioscler Thromb Vasc Biol 2007; 27: 2079-2093.
  CrossrefPubMedGoogle Scholar
• 48 Rosen ED, Roahrig J, Castellino FJ. FXI is essential for thrombus formation following ferric chloride-induced injury of the carotid artery in the mouse. Arterioscl Throm Vas 2002; 22: A61-A
  CrossrefPubMedGoogle Scholar
• 49 Weinberg PD, Ross Ethier C. Twenty-fold difference in hemodynamic wall shear stress between murine and human aortas. J Biomech 2007; 40: 1594-1598.
  CrossrefPubMedGoogle Scholar